Abstract
Objective To assess the long-term safety and effectiveness of tacrolimus as maintenance therapy in patients with lupus nephritis (LN) receiving treatment in real-world clinical settings in Japan.
Methods An open-label, non-comparative, observational, prospective post-marketing surveillance study was conducted in 1395 patients with LN receiving maintenance treatment with tacrolimus at 278 medical institutions across Japan over a period of 10 years. Tacrolimus continuation rate and cumulative incidence of adverse drug reactions (ADRs), relapse, progression to renal failure and progression to dialysis were calculated using Kaplan–Meier analysis.
Results Safety data were available for 1355 patients, almost half (49.3%) of whom remained on tacrolimus for the full 10 years of follow-up. A significant reduction in mean (SD) daily oral corticosteroid dose was observed from 16.0 (9.7) mg/day at 4 weeks after initiation of tacrolimus treatment to 7.2 (4.4) mg/day at Year 10 (p<0.001). The most frequently reported serious ADRs were infections (reported for 131 patients, [9.7%]). Except for infections, no marked increase in the incidence of any other ADRs was seen over time, including renal impairment, malignant tumors, and cardiac dysfunction. Renal function was generally well-maintained over the 10 years of follow-up. At Year 10, cumulative rates of relapse, renal failure and dialysis were 44.5%, 12.2% and 4.5%, respectively.
Conclusion Tacrolimus was effective and generally well-tolerated as maintenance therapy for LN in a large cohort of patients in Japan followed for 10 years; almost half of whom remained on therapy for the entire duration of follow-up (www.ClinicalTrials.gov: NCT01410747).
